is compounded semaglutide effective GLP-1 for Weight Loss in Roseville CA Novo Nordisk Drops Hims &

Food and Drug Administration (2026)

Although the FAERS database aids in detecting rare adverse events via spontaneous reporting, its propensity to overestimate unexpected adverse events linked to new therapies makes it inappropriate for comparative analysis of adverse event frequencies among pharmaceuticals

Preclinical work with GLP-1R/GIPR/GcgR triple agonists showed that a balanced triple agonist produced greater body-weight loss than semaglutide, tirzepatide, and dual co-agonists in diet-induced obese mice, reducing weight to near-lean levels at the highest doses

Even when researchers have looked specifically for this response in human subjects, they do not find it

Nonexpression of GLP-1R is common in advanced pancreatic tumors with lymphatic metastasis and is associated with poor prognosis, suggesting that GLP-1R may inhibit tumorigenesis and metastasis of human pancreatic cancer cells both in vitro and in vivo